Immunocytochemical analysis of apoptosis-related proteins showed that the levels of total and activated p53, a crucial participant in the apoptotic pathway, were drastically increased in bendamustine-treated myeloma cells (Fig. 8C–F). The gene discussed is TP53; the disease is plasma cell myeloma.